[225Ac]Ac-AKY-2519 for Cancer

(BActinium-2 Trial)

This trial tests a new treatment, [225Ac]Ac-AKY-2519, for individuals with certain cancers that display the B7-H3 marker on imaging scans. The goal is to determine the treatment's safety and effectiveness in shrinking tumors. It targets those with solid tumors, such as advanced lung, head and neck, esophageal, colorectal, or prostate cancer, who have not previously received similar targeted treatments. Participants must be able to give consent, follow study rules, and have measurable cancer on scans. The trial excludes individuals who have recently undergone other cancer treatments or have serious heart conditions. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the chance to be among the first to receive this new therapy.

Research has shown that Actinium-225, used in treatments like [225Ac]Ac-AKY-2519, appears safe. Studies have found no sudden harmful or life-threatening side effects from treatments using Actinium-225, indicating that patients did not face immediate dangers during treatments.

Actinium-225 emits alpha particles, which generally cause fewer side effects than beta particles. It is also approved for treating certain prostate cancers, suggesting its safety for humans.

[225Ac]Ac-AKY-2519 is unique because it uses a novel radioisotope, Actinium-225, to specifically target and destroy cancer cells. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, this treatment delivers targeted radiation therapy directly to the tumor, minimizing damage to surrounding healthy tissue. Researchers are excited about its potential for greater precision and reduced side effects, offering a promising new avenue for patients who may not respond well to existing treatments.

Research has shown that [225Ac]Ac-AKY-2519, the investigational treatment tested in this trial, is a new radiation therapy designed to directly target cancer cells. Studies have found that this treatment attaches to a protein called B7-H3, present on many cancer cells, and delivers radiation to destroy them while sparing most healthy tissues. Early results indicate that tumors absorb the drug well, which may help shrink or slow the growth of cancers like prostate cancer. The treatment has also proven safe, with minimal effects on normal tissue. These findings suggest it could effectively treat solid tumors with the B7-H3 protein.⁶⁷⁸⁹¹⁰